• 1
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 12001205.
  • 2
    Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndrome. Lancet 2000; 356: 15871591.
  • 3
    Alden C, Lin J, Smith P. Predictive toxicology technology for avoiding idiosyncratic liver injury. Preclinica 2003; May/June: 2735.
  • 4
    Gut J. Severe adverse drug reactions and theragenomics. Business Briefing Pharmatech 2002: 15.
  • 5
    Park BK, Kitteringham NR, Powell H, Pirmohamed M. Advances in molecular toxicology: towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 3960.
  • 6
    Masubuchi Y, Nakayama S, Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. HEPATOLOGY 2002; 35: 544551.
  • 7
    Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003; 192: 307322.
  • 8
    Ulrich RG, Bacon JA, Brass EP, Cramer CT, Petrella DK, Sun EL. Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem Biol Interact 2001; 134: 251270.
  • 9
    Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003; 307: 916.
  • 10
    Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002; 142: 723.
  • 11
    Hamadeh HK, Knight BL, Haugen AC, Sieber S, Amin RP, Bushel PR, et al. Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations. Toxicol Pathol 2002; 30: 470482.
  • 12
    Waring JF, Gum R, Morfitt D, Jolly RA, Ciurlionis R, Heindel M, et al. Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology 2002; 181–182: 537550.
  • 13
    Waring JF, Cavet G, Jolly RA, McDowell J, Dai H, Ciurlionis R, et al. Development of a DNA microarray for toxicology based on hepatotoxin-regulated sequences. Environ Health Perspect 2003; 111: 863870.
  • 14
    Drlica K, Zhao X. DNA gyrase, topoisomerase IV and the 4-quinolones. Microbiol Molec Biol Rev 1997; 61: 377392.
  • 15
    Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 1999; 21: 407421.
  • 16
    Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798817.
  • 17
    Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001; 47: 38.
  • 18
    Gomez-Lechon MJ, O'Connor E, Castell JV, Jover R. Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes. Toxicol Sci 2002; 65: 299308.
  • 19
    Ponsoda X, Bort R, Jover R, Gomez-Lechon MJ, Castell JV. Increased toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH. Biochem Pharmacol 1999; 58: 15791585.
  • 20
    Waring JF, Ciurlionis R, Jolly RA, Heindel M, Gagne G, Fagerland JA, et al. Isolated human hepatocytes in culture display markedly different gene expression patterns depending on attachment status. Toxicol In Vitro 2003; 17: 693701.
  • 21
    Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980; 106: 207212.
  • 22
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 5563.
  • 23
    Quillet-Mary A, Jaffrezou J-P, Mansat V, Bordier C, Naval J, Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem 1997; 272: 2138821395.
  • 24
    Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, et al. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 2001; 175: 2842.
  • 25
    Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, et al. NetAffx: affymetrix probesets and annotations. Nucleic Acids Res 2003; 31: 8286.
  • 26
    Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996; 37: 955963.
  • 27
    Modriansky M, Ulrichova J, Bachleda P, Anzenbacher P, Anzenbacherova E, Walterova D, et al. Human hepatocyte—a model for toxicological studies. Functional and biochemical characterization. Gen Physiol Biophys 2000; 19: 223235.
  • 28
    Morgan KT, Ni H, Brown HR, Yoon L, Jr CWQ, Crosby LM, et al. Application of cDNA microarray technology to in vitro toxicology and the selection of genes for a real-time RT-PCR-based screen for oxidative stress in Hep-G2 cells. Toxicol Pathol 2002; 30: 435451.
  • 29
    Garcia-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez-Checa JC. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. Mol Pharmacol 1995; 48: 825834.
  • 30
    Videla LA, Valenzuela A, Fernandez V, Kriz A. Differential lipid peroxidative response of rat liver and lung tissues to glutathione depletion induced in vivo by diethyl maleate: effect of the antioxidant flavonoid (+)-cyanidanol-3. Biochem Int 1985; 10: 425433.
  • 31
    Mizumoto K, Rothman RJ, Farber JL. Programmed cell death (apoptosis) of mouse fibroblasts is induced by the topoisomerase II inhibitor etoposide. Mol Pharmacol 1994; 46: 890895.
  • 32
    Gomez-Lechon MJ, Ponsoda X, Bort R, Castell JV. The use of cultured hepatocytes to investigate the metabolism of drugs and mechanisms of drug hepatotoxicity. Altern Lab Anim 2001; 29: 225231.
  • 33
    Guillouzo A. Liver cell models in in vitro toxicology. Environ Health Perspect 1998; 106: 511532.
  • 34
    Kier LD, Neft R, Tang L, Suizu R, Cook T, Onsurez K, et al. Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat Res 2004; 549: 101113.
  • 35
    Bottger EC, Springer B, Prammananan T, Kidan Y, Sander P. Structural basis for selectivity and toxicity of ribosomal antibiotics. EMBO J 2001; 2: 318323.
  • 36
    Eura Y, Ishihara N, Yokota S, Mihara K. Two mitofusin proteins, mammalian homologues of FZO, with distinct functions are both required for mitochondrial fusion. J Biochem (Tokyo) 2003; 134: 333344.
  • 37
    Santel A, Frank S, Gaume B, Herrler M, Youle RJ, Fuller MT. Mitofusin-1 protein is a generally expressed mediator of mitochondrial fusion in mammalian cells. J Cell Sci 2003; 116: 27632774.
  • 38
    Karbowski M, Lee Y-J, Gaume B, Jeong S-Y, Frank S, Nechushtan A, et al. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol 2002; 159: 931938.
  • 39
    Sissi C, Palumbo M. The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anti-Cancer Agents 2003; 3: 439450.
  • 40
    Anderson VE, Osheroff N. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des 2001; 7: 337353.
  • 41
    Mondal N, Parvin JD. DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates. Nature 2001; 413: 435438.
  • 42
    Mondal N, Zhang Y, Jonsson Z, Dhar SK, Kannapiran M, Parvin JD. Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity. Nucleic Acids Res 2003; 31: 50165024.